Monitor for legal action or settlement between Xencor and Alexion regarding the royalty dispute, which could impact Xencor's future revenue and valuation. The outcome will be critical for assessing Xencor's financial trajectory despite maintained cash runway.
XNCR drugs
XNCR drug pipeline →How the stock moved after the report
BEARISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Mar 5 $11.16entry
- T+1 · 9mo ago +1.43%α +2.75% · $11.32
- T+5 · 8mo ago +4.03%α +6.27% · $11.61
- T+20 · 8mo ago +14.78%α +18.57% · $12.81
- T+60 · 6mo ago +5.73%α −5.57% · $11.80
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Xencor Inc. announced that Alexion Pharmaceuticals disputes its obligation to pay U.S. royalties on Ultomiris sales, potentially forfeiting $100-120 million in expected revenue through 2028. Xencor disagrees with Alexion's position and is evaluating its options, while maintaining its cash guidance of $380-400 million by end-2026 and sufficient runway into mid-2028.
Key Facts
- Alexion Pharmaceuticals disputes obligation to pay U.S. royalties on Ultomiris sales and will not make future U.S. payments
- Xencor expected $100-120 million in additional U.S. royalties through 2028 based on patent issuance
- Xencor disagrees with Alexion's position and is evaluating its options
- Xencor maintains cash guidance of $380-400 million at end-2026 and sufficient runway into mid-2028
- Alexion will continue making royalty payments for Ultomiris sales outside the United States
Financial Impact
Loss of $100-120 million in expected royalty revenue through 2028
Risk Factors
- Potential loss of $100-120 million in expected royalty revenue
- Legal costs and uncertainty from potential litigation with Alexion
- Impact on future partnerships if intellectual property rights enforcement is perceived as weak
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001326732-26-000021 |
| Document: xncr-20260304xexx991.htm | 0001326732-26-000021 |
| Document: 0001326732-26-000021-index-headers.html | 0001326732-26-000021 |
| Document: 0001326732-26-000021-index.html | 0001326732-26-000021 |
| Document: 0001326732-26-000021.txt | 0001326732-26-000021 |
Track record
20 reports on XNCR
4 of 6 bullish or bearish reports moved the stock their way by T+1. Best: +67.24% at T+60 after the May 5, 2026 report. 5 of 6 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $35.40 Now $35.40 +0.00% settles Nov 18
- Nov 13, 20263d ago SC 13G Neutral 3/10 Entry $39.23 Now $35.40 −9.77% settles Nov 17
- Nov 12, 20264d ago Insider Cluster Neutral 4/10 Entry $37.09 to $35.40 Now $35.40 −4.56% ▼ −4.56% −2.65% vs SPY
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $38.13 to $37.09 Now $35.40 −7.16% ▼ −2.73% −2.36% vs SPY
- Nov 10, 20266d ago 144 Neutral 3/10 Entry $39.97 to $38.13 Now $35.40 −11.43% ▼ −4.60% −4.25% vs SPY
- Nov 6, 202610d ago SC 13G/A Neutral 3/10 Entry $35.75 to $38.59 Now $35.40 −0.98% ▲ +7.94% +5.58% vs SPY
- Nov 4, 202612d ago 8-K Neutral 5/10 Entry $34.05 to $35.75 Now $35.40 +3.96% ▲ +4.99% +4.68% vs SPY
- Oct 30, 202617d ago SC 13G/A Bearish 4/10 Entry $29.82 to $29.66 Now $35.40 −18.71% ▲ +0.54% +0.06% vs SPY
- Oct 27, 202620d ago SC 13G/A Neutral 2/10 Entry $29.99 to $29.21 Now $35.40 +18.04% ▼ −2.60% −2.22% vs SPY
- Oct 26, 202621d ago 8-K Bullish 6/10 Entry $29.18 to $29.99 Now $35.40 +21.32% ▲ +2.78% +2.22% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers